Microrna-Based tool for non-invasive early-stage cancer diagnosis
The goal of this project is to develop a portable and easy to use device for early cancer diagnosis to maximise patient outcomes.
Cancer is a major public health problem and a leading cause of morbidity and death with over 14.1 million cases reported worldwide
every year. Early cancer diagnosis is critical to its successful treatment, yet today’s technologies are limited in their accuracy, and are
laborious and time consuming processes.

Genomtec aims to address this challenge with its novel diagnostic system based on unique, patent pending amplification
technology – Streamlined Nucleic Acid Amplification Technology (SNAATTM). Genomtec’s programme is built on many years of R&D
activity and collaborative projects with academic and medical institutions in Poland. Using this robust molecular biology method for
real-time amplification of nucleic acids, Genomtec’s cancer diagnostic test can be performed in 20 minutes at the point-of-care.

Genomtec offers the possibility to accurately diagnose cancer early and reduce its financial burden on the economy by enabling
more effective treatment and improved patient outcomes, including increased patient survival, increased post-treatment quality of
life, and reduced patient distress during the diagnostic phase. Genomtec’s diagnostic device is unique and there are no competitors
using the same molecular approach to diagnose cancer based on detection of tumour specific microRNA.

The ultimate success of this project will depend on the generation of clinical data which will improve opportunities for sales
expansion. Genomtec plans to apply for the SME Phase 2 grant to take its product through device finalisation, clinical studies, and
establishment of the distribution network. Genomtec has an established business development contact network and has been
awarded numerous prizes for its innovativeness and potential for growth, e.g. The best non-US startup at Boston HUBWeek in
October 2018.